ArticleCancer science2017

Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.

Daisuke Honma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.